Pathway Inhibitors

Asp2215 View larger

Gilteritinib (ASP2215)

AOB0270

CAS 1254053-43-4

Chemical Name: 6-Ethyl-3-{3-methoxy-4-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-phenylamino}-5-(tetrahydro-pyran-4-ylamino)-pyrazine-2-carboxylic acid amide

For Bulk quantities: click AOB0270B

More details

Molarity Calculation Cart®

HOW TO ORDER

$11.00

$11.00 per mg

Quantity Discount Table - Order More To Get More Price Discount

QuantitymgUnit Price ($/mg or $/Unit)Final Price
1100 $4.95 Total: $495.00
150 $5.72 Total: $286.00
125 $6.71 Total: $167.75
110 $7.92 Total: $79.20
15 $9.35 Total: $46.75

Data sheet

Molecular FormulaC29H44N8O3
Molecular Weight552.71
CAS Numbers1254053-43-4
Storage Condition0°C (short term), -20°C (long term), desiccated
SolubilityDMSO
Purity98% by HPLC
SynonymASP-2215; ASP2215; ASP 2215; Gilteritinib.
IUPAC/Chemical Name6-ethyl-3-((3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)pyrazine-2-carboxamide.
InChl KeyGYQYAJJFPNQOOW-UHFFFAOYSA-N
InChl CodeInChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)
SMILES CodeO=C(C1=NC(CC)=C(NC2CCOCC2)N=C1NC3=CC=C(N4CCC(N5CCN(C)CC5)CC4)C(OC)=C3)N
References1) Yun HD, Nathan S, Larson M, Hussain MJ, Katz DA, Varma A, Miller I, Ustun C. Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD-positive acute myeloid leukemia. Blood Adv. 2019 Nov 26;3(22):3709-3712. doi: 10.1182/bloodadvances.2019000775. PubMed PMID: 31765477; PubMed Central PMCID: PMC6880901.

2) Sidaway P. Gilteritinib improves outcomes in AML. Nat Rev Clin Oncol. 2019 Nov 19. doi: 10.1038/s41571-019-0305-2. [Epub ahead of print] PubMed PMID: 31745291.

3) Smith CC, Levis MJ, Perl AE, Martinelli G, Neubauer A, Berman E, Montesinos P, Baer MR, Larson RA, Chou WC, Yokoyama H, Recher C, Yoon SS, Hill JE, Rosales M, Bahceci E.

More info

Novel FLT3/AXL inhibitor, improving outcomes in AML